Table 4. Distribution of KIR and their respective HLA ligands in patients with and without ocular toxoplasmosis and its primary or recurrent manifestations.
| KIR - HLA ligands | Patients without ocular toxoplasmosis (n = 149) | Patients with ocular toxoplasmosis (n = 148) | Patients with primary manifestation (n = 120) | Patients with recurrent manifestation (n = 28) |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | N (%) | |
| 2DL1-C2 | 123 (82.6) | 121 (81.8) | 99 (82.5) | 22 (78.6) |
| 2DL2-C1 | 55 (36.9) | 57 (38.5) | 41 (34.2) | 16 (57.1) |
| 2DL3-C1 | 79 (53.0) | 71 (48.0) | 55 (45.8) | 16 (57.1) |
| 3DL2-A3/A11 | 31 (20.8) | 42 (28.4) | 32 (26.7) | 10 (35.7) |
| 3DL1-Bw4 | 109 (71.2) | 101 (68.2) | 82 (68.3) | 19 (67.8) |
| 3DL1-Bw4-80Ile | 90 (60.4) | 81 (54.7) | 68 (56.6) | 13 (46.4) |
| 3DL1-Bw4-80Thr | 45 (30.2) | 38 (25.7) | 28 (23.3) | 10 (35.7) |
| 2DS1-C2 | 49 (32.9) | 55 (37.2) | 44 (36.7) | 11 (39.3) |
| 2DS2-C1 | 22 (14.8) | 16 (10.8) | 11 (9.2) | 5 (17.9) |
| 3DS1-Bw4-80Ile | 19 (12.8)a,b,c | 37 (25.0)a | 28 (23.3)b | 9 (32.1)c |
| 2DL1-C2C2 | 61 (40.9) | 63 (42.6) | 53 (44.2) | 10 (35.7) |
| 2DL2-C1C1 | 19 (12.8) | 20 (13.5) | 14 (21.4) | 6 (21.4) |
| 2DL3-C1C1 | 23 (15.4) | 23 (15.5) | 17 (14.2) | 6 (21.4) |
| 2DS1-C2C2 | 18 (12.1) | 31 (20.9) | 26 (21.7) | 5 (17.9) |
| 2DS2-C1C1 | 10 (6.7) | 4 (2.7) | 2 (1.7) | 2 (7.1) |
| 2DL2/2DL2-C1C2 | 6 (4.0) | 10 (6.8) | 8 (6.7) | 2 (7.1) |
| 2DL2/2DL3-C1C2 | 30 (20.1) | 27 (18.2) | 19 (15.8) | 8 (28.6) |
| 2DL3/2DL3-C1C2 | 56 (37.6)d,e,f | 21 (14.2)d | 19 (15.8)e | 2 (7.1)f |
| 2DL2/2DL2-C1C1 | 3 (2.0) | 2 (1.4) | 2 (1.7) | 0 (0.0) |
| 2DL2/2DL3-C1C1 | 16 (10.7) | 18 (12.2) | 12 (10.0) | 6 (21.4) |
| 2DL3/2DL3-C1C1 | 23 (15.4)g,h,i | 5 (3.4)g | 5 (4.2)h | 0 (0.0)i |
aOR = 2.28; CI = 1.24–4.19; P = 0.007; Pc = 0.01 (Patients without ocular toxoplasmosis vs. Patients with ocular toxoplasmosis).
bOR = 2.08; CI = 1.09–3.95; P = 0.02; Pc = 0.04 (Patients without ocular toxoplasmosis vs. Patients with primary manifestation).
cOR = 3.24; CI = 1.28–8.89; P = 0.02; Pc = 0.04 (Patients without ocular toxoplasmosis vs. Patients with recurrent manifestation).
dOR = 0.27; CI = 0.15–0.48; P = 0.000007; Pc = 0.00002 (Patients without ocular toxoplasmosis vs. Patients with ocular toxoplasmosis).
eOR = 0.31; CI = 0.17–0.56; P = 0.0001; Pc = 0.0003 (Patients without ocular toxoplasmosis vs. Patients with primary manifestation).
fOR = 0.12; CI = 0.29–0.59; P = 0.003; Pc = 0.009 (Patients without ocular toxoplasmosis vs. Patients with recurrent manifestation).
gOR = 0.19; CI = 0.07–0.51; P = 0.0005; Pc = 0.001 (Patients without ocular toxoplasmosis vs. Patients with ocular toxoplasmosis).
hOR = 0.23; CI = 0.08–0.64; P = 0.002; Pc = 0.006 (Patients without ocular toxoplasmosis vs. Patients with primary manifestation).
iOR = 0.09; CI = 0.05–0.91; P = 0.01; Pc = 0.05 (Patients without ocular toxoplasmosis vs. Patients with recurrent manifestation).